A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group

Mario E. Lacouture, Michael L. Maitland, Siegfried Segaert, Ann Setser, Robert Baran, Lindy P. Fox, Joel B. Epstein, Andrei Barasch, Lawrence Einhorn, Lynne Wagner, Dennis P. West, Bernardo L. Rapoport, Mark G. Kris, Ethan Basch, Beth Eaby, Sandra Kurtin, Elise A. Olsen, Alice Chen, Janet E. Dancey, Andy Trotti

Research output: Contribution to journalArticlepeer-review

118 Scopus citations


Background Accurate grading of dermatologic adverse events (AE) due to epidermal growth factor receptor (EGFR) inhibitors (EGFRIs) is necessary for drug toxicity determinations, interagent comparisons, and supportive care trials. The most widely used severity grading scale, the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE v4.0), was not designed specifically for this class of agents and may result in underreporting and poor grading of distinctive adverse events. We believe a class-specific grading scale is needed to help standardize assessment and improve reporting of EGFRI-associated dermatologic AEs. Methods The Multinational Association of Supportive Care in Cancer (MASCC) Skin Toxicity Study Group conducted an international multidisciplinary meeting that included 20 clinicians and researchers from academic centers and government agencies. Experts from different disciplines presented current information specific to EGFRI-induced dermatologic toxicities: grading scale development, pharmacovigilance safety reporting, health-related quality of life, patient reporting, and pharmacology. Group discussions, literature reviews, and professional expertise established the theoretical foundation for the proposed grading scale. Results A new grading system is proposed for the most common events associated with EGFRI-induced dermatologic AEs: papulopustular reaction or acneiform rash, nail changes, erythema, pruritus, xerosis, hair changes, telangiectasias, hyperpigmentation, mucositis, flushing, radiation dermatitis, hyposalivation, and taste changes. The proposed scale maintains consistency with the grading principles and language of the existing CTCAE version 4.0 and MedDRA terminology and includes relevant patient-reported healthrelated quality of life factors. Conclusions A grading scale specific to EGFR inhibitor dermatologic AEs is presented for formal integration into future versions of CTCAE and for validation in clinical trial settings. The study group designed this scale to detect and report EGFRI-related toxicities with greater sensitivity, specificity, and range than the scales currently used. This scale should serve as a foundation for efforts to perform objective interdrug comparisons and assessments of supportive care treatment strategiesmore effectively than with currentmethods.

Original languageEnglish (US)
Pages (from-to)509-522
Number of pages14
JournalSupportive Care in Cancer
Issue number4
StatePublished - Apr 2010


  • Adverse events
  • Dermatologic
  • EGFR inhibitors
  • Grading
  • Mucosa
  • Quality of life
  • Skin

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group'. Together they form a unique fingerprint.

Cite this